Skip to the reading
Long IslandPeptides

CJC 1295 research can show a hormone rise. A better day is another question.

A blood result has the comfort of a number. Sleeping better or feeling stronger is harder to sum up. When I read about CJC-1295, I try to keep both in view: what changed in the study, and what you might have hoped that change would mean.

An adult's relaxed forearm and open hand extend in a gentle waking stretch beside a bright bedroom window
An open hand and forearm in a waking stretch.

The form matters more than the shorthand

CJC-1295 is a lab-made relative of growth hormone-releasing hormone. That hormone signals the pituitary gland in the brain to release growth hormone. There’s a long-acting form and a form without the addition that makes it last.

The addition is called DAC, short for Drug Affinity Complex. It lets CJC-1295 attach to albumin, a protein in blood. In small studies of healthy adults, this long-acting form raised growth hormone and IGF-1, a related growth factor, for days.

“With DAC” is part of the finding, not a spare detail.

The FDA review says DAC and non-DAC forms are different active ingredients that aren’t interchangeable. It found no human studies of the non-DAC forms it evaluated. That’s a good reason to spell out the form whenever a finding is discussed.

A higher number still needs a meaning

The hormone rise is a real result. The studies didn’t show that people slept better, built muscle or aged more slowly. If one of those is your question, the blood result leaves it unanswered. I don’t think it needs dressing up.

The study measured hormones. It didn’t measure a better morning.

It’s easy to hear “more growth hormone” and jump to a picture of feeling better. I’d pause at the missing step: did anyone measure that benefit? A mechanism can be interesting without giving us that answer.

The same care matters when ipamorelin joins the discussion. Evidence about CJC-1295 alone doesn’t establish what a combination will do. The ingredients keep their separate records, even when their names appear on the same line.

The safety questions are still there

FDA’s safety-risk page lists increased heart rate and reactions involving widened blood vessels. Its review also raises concerns about immune reactions and limited safety data. The wider drug-class review flags blood-sugar problems and missing long-term evidence.

CJC-1295 isn’t FDA-approved. On the safety page current as of April 22, 2026, it is listed as nominated but withdrawn. Withdrawal is not FDA clearance. The page gives no individual withdrawal date.

A withdrawn nomination isn’t a safety verdict.

So I’m left with a useful but narrow finding: hormones rose in small studies of the long-acting form. Whether that brings the change you care about, and what long-term use means for safety, remain open. The questions page follows those loose ends.